Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Artigo em Inglês | MEDLINE | ID: mdl-29203485

RESUMO

Therapies for human African trypanosomiasis and Chagas disease, caused by Trypanosoma brucei and Trypanosoma cruzi, respectively, are limited, providing minimal therapeutic options for the millions of individuals living in very poor communities. Here the effects of 10 novel quinolines are evaluated in silico and by phenotypic studies using in vitro and in vivo models. Absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties revealed that most molecules did not infringe on Lipinski's rules, which is a prediction of good oral absorption. These quinolines showed high probabilities of Caco2 permeability and human intestinal absorption and low probabilities of mutagenicity and of hERG1 inhibition. In vitro screens against bloodstream forms of T. cruzi demonstrated that all quinolines were more active than the reference drug (benznidazole [Bz]), except for DB2171 and DB2192, with five (DB2187, DB2131, DB2186, DB2191, and DB2217) displaying 50% effective concentrations (EC50s) of <3 µM (4-fold lower than that of Bz). Nine quinolines were more effective than Bz (2.7 µM) against amastigotes, showing EC50s ranging from 0.6 to 0.1 µM. All quinolines were also highly active in vitro against African trypanosomes, showing EC50s of ≤0.25 µM. The most potent and highly selective candidates for each parasite species were tested in in vivo models. Results for DB2186 were promising in mice with T. cruzi and T. brucei infections, reaching a 70% reduction of the parasitemia load for T. cruzi, and it cured 2 out of 4 mice infected with T. brucei DB2217 was also active in vivo and cured all 4 mice (100% cure rate) with T. brucei infection.


Assuntos
Doença de Chagas/tratamento farmacológico , Quinolinas/farmacologia , Tripanossomicidas/farmacologia , Trypanosoma brucei brucei/efeitos dos fármacos , Trypanosoma cruzi/efeitos dos fármacos , Animais , Células CACO-2 , Linhagem Celular , Linhagem Celular Tumoral , Feminino , Humanos , Masculino , Mamíferos , Camundongos , Parasitemia/tratamento farmacológico , Ratos
2.
Int J Parasitol Drugs Drug Resist ; 8(2): 159-164, 2018 08.
Artigo em Inglês | MEDLINE | ID: mdl-29587237

RESUMO

Trypanosoma congolense is a protozoan parasite that is transmitted by tsetse flies, causing African Animal Trypanosomiasis, also known as Nagana, in sub-Saharan Africa. Nagana is a fatal disease of livestock that causes severe economic losses. Two drugs are available, diminazene and isometamidium, yet successful treatment is jeopardized by drug resistant T. congolense. Isothermal microcalorimetry is a highly sensitive tool that can be used to study growth of the extracellular T. congolense parasites or to study parasite growth inhibition after the addition of antitrypanosomal drugs. Time of drug action and time to kill can be quantified in a simple way by real time heat flow measurements. We established a robust protocol for the microcalorimetric studies of T. congolense and developed mathematical computations in R to calculate different parameters related to growth and the kinetics of drug action. We demonstrate the feasibility and benefit of the method exemplary with the two standard drugs, diminazene aceturate and isometamidium chloride. The method and the mathematical approach can be translated to study other pathogenic or non-pathogenic cells if they are metabolically active and grow under axenic conditions.


Assuntos
Antiprotozoários/farmacologia , Calorimetria/métodos , Temperatura , Tripanossomicidas/farmacologia , Trypanosoma congolense/efeitos dos fármacos , Trypanosoma congolense/crescimento & desenvolvimento , Animais , Cultura Axênica , Bovinos , Sistemas Computacionais , Diminazena/análogos & derivados , Diminazena/farmacologia , Descoberta de Drogas , Resistência a Medicamentos , Modelos Teóricos , Fenantridinas/farmacologia , Trypanosoma congolense/fisiologia , Tripanossomíase Bovina/diagnóstico , Tripanossomíase Bovina/parasitologia
3.
Acta Trop ; 108(1): 6-10, 2008 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-18722336

RESUMO

The choice of drugs for the treatment of sleeping sickness is extremely limited. To redress this situation, the recently synthesised diamidine, 2,5-bis(4-amidinophenyl)-furan (DB75, furamidine) and its methamidoxime prodrug, 2,5-bis(4-amidinophenyl)-furan-bis-O-methylamidoxime (DB289, pafuramidine) were, together with pentamidine, evaluated for efficacy in acute rodent models. The activity was compared in three common mouse models that mimic the first stage of human African trypanosomiasis. The mice were infected with the pleomorphic T .b. rhodesiense strains KETRI2537 and STIB900 or with the monomorphic T. b. brucei strain STIB795. Importantly, DB75 showed activity superior to that of pentamidine at comparable doses in all three mouse models. Complete cures were achieved with oral dosing of the prodrug DB289 in all three models without any overt toxicity. This shows that the prodrug strategy was successful in terms of reducing toxicity and increasing efficacy and oral bioavailability.


Assuntos
Antiprotozoários/uso terapêutico , Benzamidinas/uso terapêutico , Pró-Fármacos/uso terapêutico , Trypanosoma brucei gambiense/efeitos dos fármacos , Tripanossomíase Africana/tratamento farmacológico , Administração Oral , Animais , Antiprotozoários/administração & dosagem , Antiprotozoários/efeitos adversos , Benzamidinas/administração & dosagem , Benzamidinas/efeitos adversos , Feminino , Humanos , Camundongos , Estrutura Molecular , Pentamidina/administração & dosagem , Pentamidina/efeitos adversos , Pentamidina/uso terapêutico , Pró-Fármacos/administração & dosagem , Pró-Fármacos/efeitos adversos
4.
Verh Dtsch Ges Pathol ; 74: 126-9, 1990.
Artigo em Alemão | MEDLINE | ID: mdl-1708569

RESUMO

In a retrospective study the DNA-cytometric parameters stemline ploidy, stemline shoulder fraction and proliferative fraction were followed during the course of the disease in 20 patients with chronic myelogenous leukemia. Stemline ploidy and stemline shoulder fraction significantly increased whereas the proliferative fraction steadily decreased during the disease most of these changes taking place during chronic phase before the clinical onset of blast crisis. Prognostically relevant cutpoints indicating disease transformation during the next 12 months could be defined.


Assuntos
Crise Blástica/diagnóstico , DNA de Neoplasias/análise , Células-Tronco Hematopoéticas/patologia , Leucemia Mielogênica Crônica BCR-ABL Positiva/patologia , Citometria de Fluxo/métodos , Humanos , Prognóstico , Estudos Retrospectivos
5.
Anal Quant Cytol Histol ; 13(6): 433-9, 1991 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-1807286

RESUMO

The prognostic value of three DNA cytometric parameters--stemline ploidy (STL), stemline shoulder fraction (SSF) and "proliferative" fraction (PRF)--for the prediction of disease transformation and survival was examined for 20 patients with chronic myelogenous leukemia (CML) during the course of their disease and compared with two commonly used hematologic parameters (degree of leukocytosis and percentage of circulating leukemic progenitor cells). With disease progression, STL and SSF increased significantly, whereas PRF showed a steady decrease from diagnosis to blast crisis. The most significant part of these changes took place during the chronic phase, before the clinical onset of disease transformation. Hematologic parameters, in comparison, revealed significant changes later, shortly before blast crisis. The remaining duration of the chronic phase diminished from 25.5 months at the time of diagnosis, when the median STL was 2.0c, to 19.6 months for patients showing an STL of 2.1c, to 15.0 months with an STL of 2.2c and to 1.0 months for those with an STL of greater than or equal to 2.3c. Prognostically relevant limits for SSF and PRF were at 20%. When the SSF passed this limit or the PRF fell below it, the mean remaining chronic phase of these patients amounted to only 14.1 and 10.1 months. Interactive cytometry allows analysis of the DNA cytometric equivalent of changes in leukemic progenitor cells, which are well known from cytogenetic and cell kinetic studies. These three DNA cytometric parameters reflect the "natural history" of CML with the development of a cytogenetically hyperdiploid clone during disease progression in most patients and a simultaneous loss of proliferative potential on the level of myelobasts.(ABSTRACT TRUNCATED AT 250 WORDS)


Assuntos
Crise Blástica/patologia , DNA de Neoplasias/análise , Leucemia Mielogênica Crônica BCR-ABL Positiva/genética , Células-Tronco/química , Histocitoquímica , Humanos , Ploidias , Valor Preditivo dos Testes , Fatores de Risco , Taxa de Sobrevida
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA